GRAIL
GRAL
NASDAQ
IPO2024
about GRAL
Grail uses advanced genomic medicine to develop non-invasive blood tests that detect diseases early, focusing on cancer screening and diagnostics.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $99.00 | $102.52 | $98.10 | $4.0B | 2.41M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$2.46 | n/a | 53.40 | -346.17% | -245.83% | 0% |